Zuranolone: A new $16,000 postpartum depression drug is here. How will insurers handle it?
[ad_1] KQED/KFF Health News — A much-awaited treatment for postpartum depression, zuranolone, hit the market in December, promising an accessible and fast-acting medication for a debilitating illness. But most private health insurers have yet to publish criteria for when they will cover it, according to a new analysis of insurance policies. The lack of guidance could limit … Read more